跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Approvals
/
CIMA-AEMPS
/
NUVAXOVID JN.1 DISPERSION INYECTABLE
Approved
STANDARD
NUVAXOVID JN.1 DISPERSION INYECTABLE
Sanofi Winthrop Industrie
🇪🇸 Spanish Agency of Medicines and Medical Devices
Approval Date
Nov 25, 2024
Approval ID
a59bccdade27c538
Company
Sanofi Winthrop Industrie
Type
Standard
Approval Details
Approval Id
a59bccdade27c538
Drug Cima Aemps Name
NUVAXOVID JN.1 DISPERSION INYECTABLE
Register Number
1211618007
Holder Company Name
Sanofi Winthrop Industrie
Marketing Company Name
Sanofi Aventis S.A.
Holder Company Detail Path
/organization/sanofi-winthrop-industrie
Authorization Date
2024-11-25
Dosage Form
DISPERSIÓN INYECTABLE
Dose
5 microgramos/dosis
Route Of Administration
VÍA INTRAMUSCULAR
Prescription Type
Medicamento Sujeto A Prescripción Médica
Commercialized
No
Company Name
Sanofi Winthrop Industrie
Company Detail Path
/organization/sanofi-winthrop-industrie
Company Information
Pharmaceutical Company Name
SANOFI WINTHROP INDUSTRIE
Country Name
France
City Name
amilly,centre val de loire,country_fr
Address
130 RUE DE LA FONTAINE
Active Ingredients
VACUNA DE PROTEINA RECOMBINANTE DE LA ESPICULA FRENTE A COVID-19 (NOVAVAX)
5 µg/dosis
Approved
Quick Info
Agency
CIMA-AEMPS
Country
🇪🇸
Approval Date
Nov 25, 2024
Approval ID
a59bccdade27c538
Type
Standard
Back to CIMA-AEMPS Approvals
NUVAXOVID JN.1 DISPERSION INYECTABLE - CIMA-AEMPS Drug Approval Details